共 10 条
[1]
Sehestedt T(2010)Risk prediction is improved by adding markers of subclinical organ damage to score Eur. Heart J. 31 883-891
[2]
Bakris G(2010)Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial Lancet 375 1140-1142
[3]
Weber MA(2010)Cardiovascular events during differing hypertension therapies in patients with diabetes J. Am. Coll. Cardiol. 56 77-85
[4]
Mann JAF(2010)Avosentan for overt diabetic nephropathy J. Am. Soc. Nephrol. 21 527-535
[5]
De Zeeuw D(2010)Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial Lancet 376 1543-1551
[6]
Appel LJ(2010)Intensive blood-pressure control in hypertensive chronic kidney disease N. Engl. J. Med. 363 918-929
[7]
Ritz E(2010)Endothelin receptor antagonists in proteinuric renal disease: every rose has its thorn J. Am. Soc. Nephrol. 21 383-394
[8]
Wenzel R(2010)Blood pressure control in chronic kidney disease: is less really more? J. Am. Soc. Nephrol. 21 1086-1092
[9]
Lewis JB(2010)Effects of intensive blood-pressure control in type 2 diabetes mellitus N. Engl. J. Med. 362 1575-1585
[10]
Cushman WC(undefined)undefined undefined undefined undefined-undefined